Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famotidine, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - symptomatic relief of heartburn, dyspepsia and indigestion due to gastro-oesophageal reflux in adults over 18 years of age. for the treatment of duodenal ulcer; benign gastric ulcer; zollinger-ellison syndrome; prevention of relapses of duodenal ulceration. short-term (no more than 12 weeks) symptomatic relief of gastro-oesophageal reflux not responsive to conservative measures. healing of oesophageal erosion or ulceration associated with gastro-oesophageal reflux disease. prevention of relapses of symptoms and erosions or ulcerations associated with gastro-oesophageal reflux disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famotidine, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - symptomatic relief of heartburn, dyspepsia and indigestion due to gastro-oesophageal reflux in adults over 18 years of age. for the treatment of duodenal ulcer; benign gastric ulcer; zollinger-ellison syndrome; prevention of relapses of duodenal ulceration. short-term (no more than 12 weeks) symptomatic relief of gastro-oesophageal reflux not responsive to conservative measures. healing of oesophageal erosion or ulceration associated with gastro-oesophageal reflux disease. prevention of relapses of symptoms and erosions or ulcerations associated with gastro-oesophageal reflux disease.

Egyesült Államok - angol - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg in 5 ml - famotidine for oral suspension is indicated in: - short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies).  famotidine is also indicated for the short-term treatment of

Egyesült Államok - angol - NLM (National Library of Medicine)

novel laboratories, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg in 5 ml - famotidine for oral suspension is indicated in: - short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short-term treatment of

Egyesült Államok - angol - NLM (National Library of Medicine)

physicians total care, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see  clinical pharmacology in adults, clinical studies).  famotidine is also indicated for the short-term treatment of esophagitis

Egyesült Államok - angol - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: famotidine tablets are indicated in adults for the: famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse

Egyesült Államok - angol - NLM (National Library of Medicine)

remedyrepack inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h 2 ) receptor antagonists. available data with h 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with

Kanada - angol - Health Canada

apotex inc - famotidine - tablet - 20mg - famotidine 20mg - histamine h2-antagonists

Kanada - angol - Health Canada

apotex inc - famotidine - tablet - 40mg - famotidine 40mg - histamine h2-antagonists

Egyesült Államok - angol - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h 2 ) receptor antagonists. risk summary available data with h 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were ob